Ken Griffin Bicycle Therapeutics PLC Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$20.02 - $24.69 $60,060 - $74,070	-3,000 Reduced 46.88%	3,400 $68,000
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $97,150 - $151,380	-5,800 Reduced 47.54%	6,400 $159,000
Q4 2023 Feb 14, 2024	BUY	$13.29 - $22.2 $106,320 - $177,600	8,000 Added 190.48%	12,200 $220,000
Q3 2023 Nov 14, 2023	BUY	$19.9 - $26.25 $25,869 - $34,125	1,300 Added 44.83%	4,200 $84,000
Q2 2023 Aug 14, 2023	SELL	$18.95 - $28.67 $22,740 - $34,404	-1,200 Reduced 29.27%	2,900 $74,000
Q1 2023 May 15, 2023	SELL	$20.02 - $31.37 $44,044 - $69,014	-2,200 Reduced 34.92%	4,100 $87,000
Q4 2022 Feb 14, 2023	BUY	$20.37 - $32.9 $128,331 - $207,270	6,300 New	6,300 $186,000

111

40.7M

3.4K

12.4K

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $723M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.